131 TSPO expression in healthy and diseased brain 1992;89(8):3170-4. doi:10.1073/pnas.89.8.3170 52. Levitt D. Gramicidin, VDAC, porin and perforin channels. Curr Opin Cell Biol. Aug 1990;2(4):68994. doi:10.1016/0955-0674(90)90112-r 53. Le Fur G, et al. Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H] RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci. Aug 1 1983;33(5):449-57. doi:10.1016/0024-3205(83)90794-4 54. Rone MB, et al. Targeting and insertion of the cholesterol-binding translocator protein into the outer mitochondrial membrane. Biochemistry. Jul 28 2009;48(29):6909-20. doi:10.1021/bi900854z 55. Lacapere JJ, et al. Peripheral-type benzodiazepine receptor: structure and function of a cholesterolbinding protein in steroid and bile acid biosynthesis. Steroids. Sep 2003;68(7-8):569-85. doi:10.1016/ s0039-128x(03)00101-6 56. Li F, et al. Translocator Protein 18 kDa (TSPO): An Old Protein with New Functions? Biochemistry. May 24 2016;55(20):2821-31. doi:10.1021/acs. biochem.6b00142 57. Rone MB, et al. Identification of a dynamic mitochondrial protein complex driving cholesterol import, trafficking, and metabolism to steroid hormones. Mol Endocrinol. Nov 2012;26(11):186882. doi:10.1210/me.2012-1159 58. Gatliff J, et al. TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control. Autophagy. 2014;10(12):2279-96. doi:10.4161/15548627.2014.991665 59. Issop L, et al. Organelle plasticity and interactions in cholesterol transport and steroid biosynthesis. Mol Cell Endocrinol. May 22 2013;371(1-2):34-46. doi:10.1016/j.mce.2012.12.003 60. Aghazadeh Y, et al. Pharmacological regulation of the cholesterol transport machinery in steroidogenic cells of the testis. Vitam Horm. 2015;98:189-227. doi:10.1016/bs.vh.2014.12.006 61. Oke BO, et al. Cell surface localization of the peripheral-type benzodiazepine receptor (PBR) in adrenal cortex. Mol Cell Endocrinol. Sep 1992;87(13):R1-6. doi:10.1016/0303-7207(92)90248-5 62. Hirsch JD, et al. Mitochondrial benzodiazepine receptors mediate inhibition of mitochondrial respiratory control. Mol Pharmacol. Jan 1989;35(1):157-63. 63. Larcher JC, et al. Effects of peripheral benzodiazepines upon the O2 consumption of neuroblastoma cells. Eur J Pharmacol. Feb 28 1989;161(2-3):197-202. doi:10.1016/00142999(89)90843-1 64. Lejri I, et al. TSPO Ligands Boost Mitochondrial Function and Pregnenolone Synthesis. J Alzheimers Dis. 2019;72(4):1045-1058. doi:10.3233/JAD190127 65. Papadopoulos V, et al. Translocator proteinmediated pharmacology of cholesterol transport and steroidogenesis. Mol Cell Endocrinol. Jun 15 2015;408:90-8. doi:10.1016/j.mce.2015.03.014 66. Papadopoulos V, et al. Translocator protein (18 kDa): an update on its function in steroidogenesis. J Neuroendocrinol. Feb 2018;30(2)doi:10.1111/ jne.12500 67. Costa E, et al. The pharmacology of neurosteroidogenesis. J Steroid Biochem Mol Biol. Jun 1994;49(4-6):385-9. doi:10.1016/09600760(94)90284-4 68. Papadopoulos V, et al. Pregnenolone biosynthesis in C6-2B glioma cell mitochondria: regulation by a mitochondrial diazepam binding inhibitor receptor. Proc Natl Acad Sci U S A. Jun 1 1992;89(11):5113-7. doi:10.1073/pnas.89.11.5113 69. Arbo BD, et al. Therapeutic actions of translocator protein (18 kDa) ligands in experimental models of psychiatric disorders and neurodegenerative diseases. J Steroid Biochem Mol Biol. Nov 2015;154:68-74. doi:10.1016/j.jsbmb.2015.07.007 70. Porcu P, et al. Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research. J Neuroendocrinol. Feb 2016;28(2):12351. doi:10.1111/jne.12351 71. Falchi AM, et al. Intracellular cholesterol changes induced by translocator protein (18 kDa) TSPO/PBR ligands. Neuropharmacology. Aug 2007;53(2):31829. doi:10.1016/j.neuropharm.2007.05.016 72. Chung JY, et al. Cholesterol accumulation, lipid droplet formation, and steroid production in Leydig cells: Role of translocator protein (18-kDa). Andrology. May 2020;8(3):719-730. doi:10.1111/ andr.12733 73. Lacapere JJ, et al. Insight into the Structural Features of TSPO: Implications for Drug Development. Trends Pharmacol Sci. Feb 2020;41(2):110-122. doi:10.1016/j.tips.2019.11.005 74. Costa B, et al. TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy. Sci Rep. Jan 11 2016;6:18164. doi:10.1038/srep18164 75. Costa B, et al. The Anxiolytic Etifoxine Binds to TSPO Ro5-4864 Binding Site with Long Residence Time Showing a High Neurosteroidogenic Activity. ACS Chem Neurosci. Jul 19 2017;8(7):1448-1454. doi:10.1021/acschemneuro.7b00027 76. Hatty CR, et al. Protein-ligand and membraneligand interactions in pharmacology: the case of the translocator protein (TSPO). Pharmacol Res. Oct 2015;100:58-63. doi:10.1016/j.phrs.2015.07.029 77. Kletsas D, et al. Peripheral-type benzodiazepine receptor (PBR) andPBRdrug ligands infibroblast and fibrosarcoma cell proliferation: role of ERK, c-Jun and ligand-activated PBR-independent pathways. Biochem Pharmacol. May 15 2004;67(10):1927-32. doi:10.1016/j.bcp.2004.01.021 78. Bader S, et al. Differential effects of TSPO ligands on mitochondrial function in mouse microglia cells. Psychoneuroendocrinology. Aug 2019;106:65-76.
RkJQdWJsaXNoZXIy MTk4NDMw